BeyondSpring (BYSI) Long-Term Debt Issuances (2019 - 2026)

BeyondSpring (BYSI) posted Long-Term Debt Issuances of $4.4 million for Q1 2026, up 88480.0% sequentially from $5000.0 in Q4 2025.

BeyondSpring (BYSI) Long-Term Debt Issuances (2019 - 2026) Analysis & Trends

BeyondSpring has reported Long-Term Debt Issuances for 5 years, with the latest figure at $4.4 million in Q1 2026.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 2824.2% YoY) and the FY2025 annual result came in at $286000.0, down 92.69% from the prior year.
Long-Term Debt Issuances improved to $4.4 million in Q1 2026 per BYSI's latest filing, from $5000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $4.4 million in Q1 2026 and troughed at -$157000.0 in Q4 2024.
A 3-year average of $1.4 million and a median of $5000.0 in 2025 frame the typical range for Long-Term Debt Issuances.
The widest YoY moves for Long-Term Debt Issuances: up 103.18% in 2025, down 103.18% in 2025.
Over 3 years, Long-Term Debt Issuances stood at -$157000.0 in 2024, then soared by 103.18% to $5000.0 in 2025, then soared by 88480.0% to $4.4 million in 2026.
According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $4.4 million, $5000.0, and -$157000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	BeyondSpring	29.85 Mn	29.85 Mn	-	74,000.00

Download Data